The ultimate treatment goal in MS is to prevent disability over the long term. However, randomised clinical trials (RCTs) usually evaluate short-term effect of therapies on disability, in the form of confirmed disability progression (CDP) after 3 and 6 months. Additionally, CDP events overestimate the accumulation of irreversible disability by up to 30% . Changes in bowel and bladder function, and in pyramidal, cerebellar, and cerebral domains contribute more to confirmed EDSS worsening than other neurological domains .
Using the global MSBase registry, Prof. Tomas Kalincik (University of Melbourne, Australia), studied 6-month CDP events as indicators of long-term disability worsening. A total of 11,435 CDP events were identified in 6,902 patients.
This study showed that CDP can be defined in more detail at the occurrence of a CDP event. A low probability of recovery from a CDP event is associated with several factors, such as older age, male ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Selpercatinib (LOXO-292) Shows Durable Activity in RET Fusion-positive Lung Cancer Next Article
Serum immunoglobulin levels and risk of serious infections »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.